Literature DB >> 15685397

Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation.

Susanne Rohrbach1, Bernd Niemann, Rolf-Edgar Silber, Juergen Holtz.   

Abstract

Membrane-bound and secreted neuregulin isoforms induce growth, survival and differentiation by activating erbB tyrosine kinase receptors. In cultured cardiomyocytes, erbB2 and erbB4 receptors regulate apoptosis by controlling bcl-x splicing, and conditional elimination of erbB2 induces dilative cardiomyopathy in vivo. Therefore, we analyzed expression and activation of erbB receptors in left ventricular myocardium from 32 heart failure patients, from 10 organ donors, and from 15 heart failure patients prior to and following unloading by ventricular assist devices. ErbB receptors, expressed in cardiomyocytes and noncardiomyocytes, are downregulated in failing myocardium as mRNA (which is renormalized by hemodynamic unloading) and as protein (erbB2: -25%; erbB4: -70%), their phosphorylation is reduced and bcl-x splicing is shifted towards 6.7-fold augmentation of proapoptotic Bcl-xS, compatible with attenuated erbB signaling. However, secreted and membrane-anchored neuregulin-1 isoforms, preferentially expressed in microvascular endothelium, are induced and not lowered with heart failure, while expression of erbB-inhibitory neuregulin isoforms or of autoinhibitory soluble erbB isoforms could not be demonstrated as potential causes of erbB receptor inhibition. We conclude that erbB receptor inactivation by unknown mechanisms results in altered splicing of bcl-x towards enhanced formation of proapoptotic Bcl-xS, thereby contributing to enhanced apoptotic susceptibility of failing human myocardium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685397     DOI: 10.1007/s00395-005-0514-4

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  44 in total

1.  Neuregulin in heart failure : reverse translation from cancer cardiotoxicity to new heart failure therapy.

Authors:  C A Geisberg; D J Lenihan
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 2.  Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis.

Authors:  Nadia Hedhli; Kerry Strong Russell
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

3.  Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.

Authors:  Laura Pentassuglia; Michael Graf; Heidi Lane; Yukio Kuramochi; Gregory Cote; Francesco Timolati; Douglas B Sawyer; Christian Zuppinger; Thomas M Suter
Journal:  Exp Cell Res       Date:  2009-02-12       Impact factor: 3.905

4.  The growth factor receptor ERBB2 regulates mitochondrial activity on a signaling time scale.

Authors:  Nirav Patel; Antoni Barrientos; Ralf Landgraf
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 5.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

Review 6.  The role of Neuregulin-1beta/ErbB signaling in the heart.

Authors:  Laura Pentassuglia; Douglas B Sawyer
Journal:  Exp Cell Res       Date:  2008-09-03       Impact factor: 3.905

Review 7.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

8.  c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia.

Authors:  Khadija Rafiq; Mikhail A Kolpakov; Rachid Seqqat; Jianfen Guo; Xinji Guo; Zhao Qi; Daohai Yu; Bhopal Mohapatra; Neha Zutshi; Wei An; Hamid Band; Archana Sanjay; Steven R Houser; Abdelkarim Sabri
Journal:  Circulation       Date:  2014-02-28       Impact factor: 29.690

Review 9.  Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics.

Authors:  Simon Braumann; Stephan Baldus; Roman Pfister
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

10.  The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction.

Authors:  Saghir Akhtar; Ibrahim Fadil Benter
Journal:  Bioimpacts       Date:  2013-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.